Tempus AI CEO Eric Lefkofsky sells $6.58 million in shares

Tempus AI (TEM) CEO Eric Lefkofsky executed a required “sell to cover” of 132,591 shares on Aug. 18 for ~$6.58M (avg. $49.61), driven by RSU tax withholding—while TEM has since risen to $66.65 (+34% vs. the sale price). Separately, Q2 2026 revenue increased 22% YoY to $382.5M but missed the $390.9M projection, leading to multiple target cuts (e.g., H.C. Wainwright $64→$56; BTIG $80→$70; Stifel $60→$50) as analysts flagged margin pressure even though EPS was better than expected (loss of $0.04 vs. -$0.08). Overall, the earnings mix (revenue miss vs. EPS outperformance) and valuation concerns point to a cautious near-term read-through for the stock.

Analysis

The share sale is almost certainly mechanical, so the real signal is not insider caution but how aggressively the stock has re-rated on limited fundamental improvement. When a name with a still-early profitability profile runs this hard in a week, the market is effectively paying up for an accelerated margin story and/or strategic optionality; that makes the tape fragile if the next data point is only “good,” not “great.”

The more important second-order issue is relative positioning inside healthcare tech/diagnostics. If Tempus continues to use acquisitions and new approvals to grow topline, smaller-multiple incumbents with cleaner operating leverage—think NTRA, DGX, and to a lesser extent ILMN as a tools proxy—can look more attractive on a risk-adjusted basis. If, however, integration costs from Ambry persist, the market may start treating TEM less like a compounding platform and more like a roll-up, which usually earns a lower terminal multiple.

Contrarian take: consensus may be over-focusing on the founder sale and underestimating that it was tax-driven, while underweighting the valuation risk embedded in a $12B cap on still-uneven margins. The next 1-3 months matter more than the headline quarter: if management does not raise margin or EBITDA expectations, the stock can easily give back 15-20% of the recent move. Over 6-18 months, the thesis flips only if oncology volume, test approvals, and acquired revenue translate into durable operating leverage rather than just more scale.

Key Decisions for Investors

• Short TEM vs long NTRA or DGX on a 1-3 month horizon; use the recent momentum to leg in, and cover if Tempus raises FY margin/EBITDA guidance or shows clear post-Ambry gross-margin expansion.
• If expressing downside directly, buy a defined-risk TEM put spread (e.g., 60/50 strikes) into the next earnings window; thesis is a 15-20% retracement if growth beats do not come with margin improvement.
• For existing TEM longs, trim 25-33% into strength above current levels and re-add only after a quarter that proves operating leverage, not just revenue growth.
• Watch for a guidance revision or integration commentary on Ambry; that is the real falsifier. A maintained/raised gross-margin outlook would invalidate the short thesis quickly.